

FY 2023 Fourth Quarter Report

April-June 2023





Arkansas Department of Health

BreastCare Quarterly Report

April-June Fiscal Year 2023



Funded by the Arkansas Department of Health (ADH) with support from the Centers for Disease Control and Prevention (CDC) and Arkansas Tobacco Excise Tax.

Table 1: Number of Women Enrolled¹, FY 2023

Funding Source	Number of Women Enrolled April-June, FY 2023	Number of Women Enrolled To-Date, FY 2023	
Total	3,225	11,572	
Federal	2,089	7,177	
State	1,136	4,395	

Data source: FY 2023 BreastCare Online System Data.

Table 2: BreastCare Funds by Expenditures and Percent Spent on Clinical Services, FY 2023

Month	April	Мау	June	April - June Average	Monthly Average To-Date FY 2023
Total Expenditures	\$385,728	\$394,237	\$458,066	\$412,677	\$402,109
Expenditures on Clinical Services	\$302,077	\$316,606	\$382,584	\$333,755	\$300,116
Percent of Expenditures Spent on Clinical Services	78.3%	80.3%	83.5%	80.9%	74.6%

Data Source: Monthly BreastCare Financial Status Report

¹Unduplicated count of women enrolled in the BreastCare Program during the period.

Table 3: Number and Percent of Screenings Performed, FY 2023

Provider Type	Number of Screenings ¹ , Apr-Jun, FY 2023	Number of Screenings ¹ , To-Date, FY 2023	Percent of Screenings, FY 2023
Health Department Clinic	2,169	7,880	55.7%
Community Health Center	757	2,619	18.5%
Hospital	790	2,945	20.8%
Private Provider	211	709	5.0%
Total ¹	3,927	14,153	100.0%

Data source: FY 2023 BreastCare Online System Data.

Table 4: Number of Screening Tests Performed through BreastCare, FY 2023

Type of Test	Number of Tests Performed Apr-Jun, FY 2023	Number of Tests Performed To-Date, FY 2023
Clinical Breast Exam ¹	1,341	4,899
Mammograms ²	970	3,529
Pap Tests ³	1,616	5,725

Data source: FY 2023 BreastCare Online System Data.

Table 5: Mammogram Screening History at Enrollment, Women 40 – 64 years old, FY 2023

Last Mammogram	Percent of Enrollees Apr-Jun, FY 2023	Percent of Enrollees To-Date, FY 2023
Within 2 Years	49.2%	50.5%
More than 2 Years	26.9%	24.3%
Never Had Mammogram	23.9%	25.2%

¹Unique screening tests performed during the period. Screening tests include clinical breast exams, screening mammograms, and Pap tests.

¹Number of clinical breast exam performed during the period, clients may receive more than one clinical breast exam.

²Number of screening mammograms performed during the period, clients may receive more than one screening mammogram.

³Number of Pap tests performed during the period, clients may receive more than one Pap test.

Table 6: Number of Cancer and Precancer Diagnoses Reported among BreastCare Women, FY 2023

Type of Diagnosis	Number of Diagnoses April-June, FY 2023		Number of Diagnoses To-Date FY 2023	
	Total	(Age < 40)	Total	(Age < 40)
Hyperplasia ¹	3	(1)	17	(3)
Atypical Hyperplasia ²	0	(0)	4	(0)
In Situ Breast Cancer ³	3	(0)	14	(3)
Breast Cancer⁴	8	(3)	34	(7)
Cervical Precancer ⁵	23	(15)	78	(53)
Cervical Cancer ⁶	3	(1)	5	(3)

Data source: FY 2023 BreastCare Online System (BOS) Data

Table 7: BreastCare Funds by Funding Source (Revenue and Expenditures) and Percent Spent on Clinical Services, FY 2020-2023

Funding Source	FY 2020	FY 2021	FY 2022	FY 2023 (Budgeted)
Federal				
Revenue	\$1,700,000	\$1,700,000	\$1,700,000	\$2,500,000
Expenditures	\$1,637,220	\$1,553,049	\$1,599,714	\$2,500,000
State				
Revenue	\$3,202,990	\$3,224,579	\$3,195,344	\$3,088,494
Expenditures	\$2,710,321	\$3,217,868	\$3,415,132	\$3,088,494
Percent of Expenditures Spent on Clinical Services	72%	65%	72%	70%

Data Source: BreastCare Monthly Budget Report

¹Unduplicated count of women with a biopsy diagnosis of hyperplasia reported in BOS during the period.

²Unduplicated count of women with a biopsy diagnosis of atypical hyperplasia reported in BOS during the period.

³Unduplicated count of women with a final diagnosis of in situ breast cancer (DCIS/LCIS) reported in BOS during the period.

⁴Unduplicated count of women with a final diagnosis of invasive breast cancer reported in BOS during the period.

⁵Unduplicated count of women with a final diagnosis of moderate or severe dysplasia (CIN-2/CIN-3) reported in BOS during this period.

⁶Unduplicated count of women with a final diagnosis of invasive cervical cancer reported in BOS during the period.

Table 8: BreastCare Clinical Services¹ Expenditures by Funding Source, FY 2020-2023

Funding Source	FY 2020	FY 2021	FY 2022	FY 2023 (Budgeted)
Federal Grant	\$1,324,515	\$1,272,753	\$1,361,448	\$1,594,000
State Tobacco Excise Tax	\$1,817,189	\$1,809,999	\$1,908,096	\$1,868,000
Total	\$3,141,704	\$3,082,752	\$3,269,544	\$3,462,000
Total Number of Women Served	9,026	8,411	9,339	9,805
Average Cost of Each Woman Served	\$348.07	\$366.51	\$350.10	\$353.09

Data source: BreastCare Budget

¹Clinical Services - Direct service provided to women who enroll in the program. These services consist of screening, diagnostic and case management services as well as salaries for Nurse Practitioners and Public Health Nurses who provide one-on-one services.

Table 9: Clinical Services Provided by BreastCare Funding Sources, FY 2022

Funding Source	Number of Women Enrolled ¹ (% of total)	Number of Women Served ^{2,4} (% of total)	Number of Women Screened ^{3,4} (% of total)
Federal	6,589	5,523	5,266
State	4,046	3,816	3,666
Total	10,635	9,339	8,932

Data Source: FY 2022 BreastCare Online System Data

¹Unduplicated count of women enrolled into BreastCare during the period.

²Unduplicated count of women receiving any clinical service through BreastCare during the period. Clinical services are related to breast and cervical cancers including screening and diagnostic procedures.

³Unduplicated count of women who received any screening procedure through BreastCare during the period. Screening procedures include clinical breast exams, mammograms and Pap tests.

⁴Numbers may change based on billing cycles and delays.

Definitions Used in This Report:

Updated: October, 2022

- 1. <u>Women enrolled</u>: Unduplicated count of women enrolled into the ADH BreastCare Program during a specified time period; *Source of report: BreastCare Online System*.
- 2. <u>Women served</u>: Unduplicated count of women receiving <u>any</u> clinical service through BreastCare Program during a specified time period. Clinical services include screening and diagnostic procedures; *Source of report: BreastCare Online System*.
- 3. <u>Women screened</u>: Unduplicated count of women receiving <u>any</u> screening procedure through BreastCare Program during a specified time period. Screening procedures include clinical breast exam, screening mammogram, and Pap test; *Source of report: BreastCare Online System.*
- 4. <u>Screenings by provider type</u>: Unduplicated count of screening procedures through BreastCare Program during a specified time period. Screening procedures include clinical breast exam, conventional mammogram, digital mammogram, conventional Pap test, and liquid-based Pap test; *Source of report: BreastCare Online System*.
- 5. <u>Clinical Breast Exams performed</u>: Number of clinical breast exams provided by BreastCare Program, sometimes more than one for the same client, during a specific time period; *Source of Report: BreastCare Online System*.
- 6. <u>Mammograms performed</u>: Number of screening mammograms provided by BreastCare Program, sometimes more than one for the same client, during a specified time period; *Source of Report: BreastCare Online System*.
- 7. <u>Pap tests performed</u>: Total number of Pap tests provided by BreastCare Program, sometimes more than one for the same client, during a specified time period; *Source of Report: BreastCare Online System.*
- 8. <u>Breast cancer diagnosis</u>: Unduplicated count of women with a final diagnosis of invasive breast cancer reported to the BreastCare program during a specific time period. The diagnosis may be prior to the quarter it is reported in; *Source of Report: BreastCare Online System*.
- 9. <u>In Situ Breast cancer diagnosis</u>: Unduplicated count of women with a final diagnosis of in situ breast cancer (DCIS/LCIS) reported to the BreastCare program during a specific time period. The diagnosis may be prior to the quarter it is reported in; *Source of Report: BreastCare Online System.*
- 10. <u>Cervical cancer diagnosis</u>: Unduplicated count of women with a final diagnosis of invasive cervical cancer reported to the BreastCare program during a specific time period. The diagnosis may be prior to the quarter it is reported in; *Source of Report: BreastCare Online System.*
- 11. <u>Cervical precancer diagnosis</u>: Unduplicated count of women with a final diagnosis of moderate or severe dysplasia (CIN-2 or CIN-3) reported to the BreastCare program during a specific time period. The diagnosis may be prior to the quarter it is reported in; Source of Report: BreastCare Online System

- 12. <u>Hyperplasia diagnosis</u>: Unduplicated count of women with a final diagnosis of hyperplasia reported to the BreastCare program during a specific time period. The diagnosis may be prior to the quarter it is reported in; *Source of Report: BreastCare Online System*
- 13. <u>Atypical hyperplasia diagnosis</u>: Unduplicated count of women with a final diagnosis of atypical ductal hyperplasia reported to the BreastCare program during a specific time period. The diagnosis may be prior to the quarter it is reported in; *Source of Report: BreastCare Online System*